ADAPTIVE AND INNATE IMMUNE RESPONSES
TRIGGERED TO NEUTRALIZE GASTRIN HORMONES
AS A THERAPY FOR GI CANCERS

PRODUCT


TYG100
TYG oncologys first product candidate, TYG100, is a reversible cancer immunotherapy (RCI), for treatment of gastroenterological cancers such as pancreatic, stomach and colon cancer. TYG100 contains G17 (little gastrin) as tumour associated autoantigen.

Over $230M has been invested. Over 1100 patients have participated in clinical trials with no serious adverse effects to prove that hormone neutralization therapy is efficacious. Phase-III
*) clinical studies of the earlier drug candidate (G17DT, a therapeutic vaccine developed by Aphton Inc.) aiming at gastrin neutralization, demonstrated survival benefit (P<0.003) with good quality of life in responding patients. G17DT clinical trial design populations were minimal and immune-responder rates were statistically incomplete to justify regulatory approval.

A recent study in non human primates with TYG100 shows that TYG100 is the superior successor of G17DT. TYG100 promises to achieve > 100 fold higher anti-G17 IgG titres in almost 100% of the patients, thereby enabling an early regulatory approval pathway with a pivotal Phase II trial.

*) An International Multicenter Randomized Controlled Trial of G17DT in Patients With PDAC”, Gilliam A.D. et al, Pancreas 2011 www.pancreasjournal.com

[Sleeker_special_clear]